294 related articles for article (PubMed ID: 28746779)
1. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.
Nobili V; Alisi A; Mosca A; Della Corte C; Veraldi S; De Vito R; De Stefanis C; D'Oria V; Jahnel J; Zohrer E; Scorletti E; Byrne CD
Liver Int; 2018 Feb; 38(2):342-349. PubMed ID: 28746779
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
3. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
[TBL] [Abstract][Full Text] [Related]
5. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
Schumacher JD; Guo GL
Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
[TBL] [Abstract][Full Text] [Related]
7. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
8. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
9. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
[TBL] [Abstract][Full Text] [Related]
10. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
Mosca A; Nobili V; De Vito R; Crudele A; Scorletti E; Villani A; Alisi A; Byrne CD
J Hepatol; 2017 May; 66(5):1031-1036. PubMed ID: 28214020
[TBL] [Abstract][Full Text] [Related]
11. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding.
Thöni V; Pfister A; Melmer A; Enrich B; Salzmann K; Kaser S; Lamina C; Ebenbichler CF; Hackl H; Tilg H; Moschen AR
J Clin Endocrinol Metab; 2017 Aug; 102(8):2974-2984. PubMed ID: 28591793
[TBL] [Abstract][Full Text] [Related]
13. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
14. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
[TBL] [Abstract][Full Text] [Related]
15. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
17. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
[TBL] [Abstract][Full Text] [Related]
18. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment.
Zhu L; Baker RD; Zhu R; Baker SS
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548
[TBL] [Abstract][Full Text] [Related]
19. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T
Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428
[TBL] [Abstract][Full Text] [Related]
20. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
